Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
Date:8/4/2009

w.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information, please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements, including statements regarding the Company's financial position and results of operations, business objectives and strategic goals, drug development plans, the potential safety and efficacy of its products in development, and commercialization and partnering strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of th
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
2. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
3. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
4. Poniard Pharmaceuticals Files Shelf Registration
5. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
6. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
9. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
10. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
11. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Delaware , June 18, 2013 ... announce the release of the HELM biomolecular representation ... open source MIT licence. HELM (Hierarchical ... a wide range of biomolecules (e.g. proteins, nucleotides, ... existing small-molecule and sequence-based informatics methodologies impractical or ...
(Date:6/18/2013)... The "Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research ... Analysis Services) & Application (Genomics, Proteomics & Drug Design) - Global Forecasts ... and Opportunities in North America , ... Rest of World. Browse , ... 364 Pages and an in-depth Table ...
(Date:6/18/2013)... 2013 Research and ... addition of the report " DNA Sequencing ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of human genome variations, development of sequencing ... small sequencers are described as well as ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 ... Markets ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced ... American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes ... Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, ... to 2017" report to their ...
Breaking Biology Technology:The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3
... County Facility To Create At Least 260 Jobs, ... Edward G. Rendell helped to break ground today ... Group, a Northern Ireland-based provider,of research, development and ... Last October, Governor Rendell announced a state investment ...
... July 23 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... to discuss its financial results for the quarter ended ... on Wednesday, July 30,2008, after the capital markets close., ... call will be hosted by senior management and will ...
... OLATHE, Kan., July 23 A national site,selection magazine ... states in the,nation for biotechnology, along with states such ... rankings report, Business Facilities reported:,"Kansas and Florida broke into ... these two states have made it clear they intend ...
Cached Biology Technology:Pennsylvania Governor Rendell Breaks Ground for Global Pharmaceutical Services Company's North American Headquarters 2Pennsylvania Governor Rendell Breaks Ground for Global Pharmaceutical Services Company's North American Headquarters 3Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results 2Kansas Breaks Into Top 10 in the Nation in Biotech Strength 2
(Date:6/17/2013)... June 17, 2013 An international team led by ... Hughes Medical Institute and Albert Einstein College of Medicine ... anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in ... to help solve one of the major global health ... dangerous drug-resistant strains," said Peter G. Schultz, the Scripps ...
(Date:6/17/2013)... improving original foundations with more modern elements. Using this ... Kenneth P. Dietrich School of Arts and Sciences have ... delivery, gas storage, and gas transport more efficient and ... the latest issue of the Journal of the ... recent work builds upon Pitt Associate Professor of Chemistry ...
(Date:6/17/2013)... Kansas State University research associate has received a prestigious ... to prevent the spread of malaria. , Bart Bryant, ... of Health,s National Research Service Award Individual Postdoctoral Fellowship, ... seventh Kansas State University researcher to receive the award ... hold such an award. , Bryant, a university doctoral ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4'Chemical architects' build materials with potential applications in drug delivery and gas storage 2NIH fellowship helps researcher fight malaria, understand mosquito immunity 2
... Hooker, an assistant chemist at the U.S. Department of ... at the Athinoula A. Martinos Center for Biomedical Imaging, ... of the Presidential Early Career Award for Scientists and ... kinds of chemicals used in biomedical imaging (see links ...
... at the University of California, San Diego School of ... of federally approved drugs to more than 1,000 proteins ... opening new avenues to repurpose these drugs to treat ... PLoS Computational Biology . "Tuberculosis is currently ...
... a seagoing fish called Alaskan pollock, may someday be put ... chemist Bor-Sen Chiou is developing strong yet pliable sheets, known ... blend of gelatin from the fish skins and a bioplastic ... sugar. The fish- and corn-derived films might be ...
Cached Biology News:Brookhaven chemist Jacob Hooker receives Presidential Early Career Award 2Brookhaven chemist Jacob Hooker receives Presidential Early Career Award 3TB-drugome provides new targets for anti-tuberculosis drug discovery 2Fish gelatin: Ultra-high-tech biomedical uses ahead? 2
...
One-step, microplate or cuvet, colorimetric, detection range 0.04% to 4%. Procedure: 30 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
...
Biology Products: